<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<style type="text/css" style="display:none"><!-- p { margin-top: 0px; margin-bottom: 0px; }--></style>
</head>
<body dir="ltr" style="font-size:12pt;color:#000000;background-color:#FFFFFF;font-family:Calibri,Arial,Helvetica,sans-serif;">
<div>PRO GRADU PROJECT ON PATIENT DERIVED OVARIAN CANCER CELL DRUG TESTING</div>
<div><br>
</div>
<div>Pro gradu student position is available in the Translational Cancer Research group at the</div>
<div>Research Center for Cancer in the Institute of Biomedicine. Our laboratory studies high</div>
<div>grade serous ovarian cancer (HGS-OvCa), with the aim of improving diagnostics and</div>
<div>treatment.</div>
<div><br>
</div>
<div>HGS-OvCa is the most common and aggressive subtype of ovarian cancer. The standard</div>
<div>therapy for HGS-OvCa patients is platinum-taxane chemotherapy together with surgery.</div>
<div>Most tumors respond to chemotherapy but, treatment resistance occurs eventually.</div>
<div>Reasons for relapse are currently largely unknown and treatment options are very</div>
<div>limited. Better means to study chemoresistance are needed. To study new more efficient</div>
<div>drug combinations, we have gathered an exceptional collection of patient derived HGSOvCa primary cancer cell lines and other clinical samples.</div>
<div><br>
</div>
<div>In this project we aim to study DNA damage and repair (disturbed homologous</div>
<div>recombination, HR) on drug sensitivity and resistance in HGS-OvCa cancer cells. We aim</div>
<div>to identify with functional ex vivo assay HR-deficient and HR-proficient primary HGSOvCa cells. Furthermore, we want to study novel drug molecules that affect the genomic</div>
<div>repair systems and cell cycle and thereby cancer cell survival.</div>
<div><br>
</div>
<div>This Pro Gradu -project will involve several cell and molecular biology techniques,</div>
<div>including e.g. primary cell culture, in vitro drug testing, microscopy techniques, imaging</div>
<div>with fluorescence microscopy, western blot and PCR to study drug combinations and HR</div>
<div>system. The aim of the project is to find possible drug combinations to target HGS-OvCa</div>
<div>cells.</div>
<div><br>
</div>
<div>We are looking for highly motivated candidates with a suitable background in the field of</div>
<div>biomedicine, cell biology, molecular biology or biochemistry. The student will have an</div>
<div>opportunity to work in a productive, interactive and international environment in the</div>
<div>new Medisiina D laboratory facilities. Previous hands-on experience in basic cell or</div>
<div>molecular biology techniques is an advantage.</div>
<div><br>
</div>
<div>The applications can be written in Finnish, English or Swedish. For further information,</div>
<div>please contact PhD Katja Kaipio or M.Sc. Pia Roering, email: kaanka@utu.fi or</div>
<div>piaroe@utu.fi<br>
</div>
<div>**********************</div>
<div>Viestin välitti</div>
<div>Fanni Suomi</div>
<div>Tiedotusvastaava, TYK ry</div>
<div>tiedotus@tykry.fi<br>
</div>
<p><br>
</p>
</body>
</html>